Peptide Therapeutics Market By Application, By Route of administration, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
3.7. Patent Landscape

CHAPTER 4: PEPTIDE THERAPEUTICS MARKET, BY APPLICATION
4.1 Overview
4.1.1 Market size and forecast
4.2 Metabolic
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Oncology
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Gastrointestinal
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Neurological
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Cardiovascular
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Others
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country

CHAPTER 5: PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Oral
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Parenteral
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country

CHAPTER 6: PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.2.4 Hospital pharmacies Peptide Therapeutics Market by Hospital type
6.2.4.1 Private Market size and forecast, by region
6.2.4.2 Public Market size and forecast, by region
6.3 Drug store and retail pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online pharmacies
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country

CHAPTER 7: PEPTIDE THERAPEUTICS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Application
7.2.3 North America Market size and forecast, by Route of administration
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.4.1 North America Hospital pharmacies Peptide Therapeutics Market by Hospital type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Market size and forecast, by Application
7.2.5.1.2 Market size and forecast, by Route of administration
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Application
7.2.5.2.2 Market size and forecast, by Route of administration
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Application
7.2.5.3.2 Market size and forecast, by Route of administration
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Application
7.3.3 Europe Market size and forecast, by Route of administration
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.4.1 Europe Hospital pharmacies Peptide Therapeutics Market by Hospital type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Application
7.3.5.1.2 Market size and forecast, by Route of administration
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Application
7.3.5.2.2 Market size and forecast, by Route of administration
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Application
7.3.5.3.2 Market size and forecast, by Route of administration
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Application
7.3.5.4.2 Market size and forecast, by Route of administration
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Application
7.3.5.5.2 Market size and forecast, by Route of administration
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Application
7.3.5.6.2 Market size and forecast, by Route of administration
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Application
7.4.3 Asia-Pacific Market size and forecast, by Route of administration
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.4.1 Asia-Pacific Hospital pharmacies Peptide Therapeutics Market by Hospital type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Application
7.4.5.1.2 Market size and forecast, by Route of administration
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Application
7.4.5.2.2 Market size and forecast, by Route of administration
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Application
7.4.5.3.2 Market size and forecast, by Route of administration
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Application
7.4.5.4.2 Market size and forecast, by Route of administration
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Application
7.4.5.5.2 Market size and forecast, by Route of administration
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Application
7.4.5.6.2 Market size and forecast, by Route of administration
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Application
7.5.3 LAMEA Market size and forecast, by Route of administration
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.4.1 LAMEA Hospital pharmacies Peptide Therapeutics Market by Hospital type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Application
7.5.5.1.2 Market size and forecast, by Route of administration
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Application
7.5.5.2.2 Market size and forecast, by Route of administration
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Application
7.5.5.3.2 Market size and forecast, by Route of administration
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Application
7.5.5.4.2 Market size and forecast, by Route of administration
7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 Eli Lilly and Company
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Amgen Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Pfizer Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Takeda Pharmaceutical Company Limited
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Novo Nordisk A/S
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Sanofi SA
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Ever Neuro Pharma GmbH
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Baush Health
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 GlaxoSmithKline plc
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Abbvie ( Allergan)
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

Executive Summary

According to this report, titled, 'Peptide Therapeutics Market,' the peptide therapeutics market was valued at $33.3 billion in 2021, and is estimated to reach $64.3 billion by 2031, growing at a CAGR of 6.8% from 2022 to 2031.

A special class of pharmacological drugs known as therapeutic peptides is made up of a sequence of well-ordered amino acids and typically has a molecular weight of 500-5000 Da. Approved peptides drugs are indicated to treat a wide array of clinical indications, including diabetes, gastric & metabolic disorders, and hormonal disorders.

Increase in elderly population and surge in cases of chronic diseases are the major drivers of this market. Peptide therapeutics are used for treating metabolic, oncology, gastrointestinal, neurological, cardiovascular and other diseases According to the Centre of Disease Control and Prevention one person dies every 34 seconds in the U.S. from cardiovascular disease. About 697,000 people in the United States died from heart disease in 2020—that’s 1 in every 5 deaths. Thus, the rise in the number of the cardiovascular disease cases around the globe along with rise in the number of the geriatric patients, leads to the growth of the market.

Furthermore, innovations, development of advanced technologies, are the peptide therapeutics market trends adopted by the key players and increasing awareness for peptide therapeutics fuels the market growth. However, high cost associated with drug discovery and less bioavailability of peptides, is expected to hinder the market growth. Conversely increasing growth opportunity in emerging markets, rising health care expenditure is a great opportunity for key players to invest in the forecast period especially in the developing economies.

The peptide therapeutics market analysis is segmented by application, route of administration, distribution channel and region. By application, the market is segmented into metabolic, oncology, gastrointestinal, neurological, cardiovascular and others. The metabolic segment dominated the peptide therapeutics market share in 2021, accounting owing to high prevalence of metabolic disorders and growing geriatric population susceptible to metabolic disorder. The oncology segment is expected to witness highest CAGR during the forecast period, owing to rise in cases of cancer globally and the presence of a strong product pipeline.

Depending on route of administration, the market is divided into oral and parenteral. The parenteral segment dominated the peptide therapeutics market size in 2021, owing to high rate of acceptance, quick drug delivery, and simple application. The oral segment is expected to witness highest CAGR during the peptide therapeutics market forecast period owing to compliance with oral route and acceptance by patients.

Depending on distribution channel, the market is divided into hospital pharmacies, drug store & retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the peptide therapeutics market size in 2021, with owing to all primarily responsible for monitoring the availability of all medications used in hospitals. The drug store & retail pharmacies segment is expected to witness highest CAGR during the forecast period owing to maintenance of treatment for long time and easy availability of drugs.

North America accounted for a majority of the global peptide therapeutics market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in peptide therapeutics development techniques, rise in cardiovascular diseases, presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing rise in geriatric population, development of healthcare infrastructure and increase in investments projects in the region.

Key findings of the study

• By application, the metabolic segment was the highest contributor to the peptide therapeutics industry in 2021.
• By route of administration, the parenteral segment was the highest contributor to the peptide therapeutics industry in 2021.
• Depending on distribution channel, the hospital pharmacies segment was highest contributor in 2021, and is expected to continue this trend during the forecast period.
• Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Companies Mentioned

• Eli Lilly and Company
• Amgen Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Novo Nordisk A/S
• Sanofi SA
• Ever Neuro Pharma GmbH
• Baush Health
• GlaxoSmithKline PLC
• Abbvie ( Allergan)

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.